Insulin resistance results from several pathophysiologic mechanisms, including chronic tissue inflammation and defective insulin signaling. We found that liver, muscle and adipose tissue exhibit higher levels of the chemotactic eicosanoid LTB4 in obese highfat diet (HFD)-fed mice. Inhibition of the LTB4 receptor Ltb4r1, through either genetic or pharmacologic loss of function, led to an anti-inflammatory phenotype with protection from insulin resistance and hepatic steatosis. In vitro treatment with LTB4 directly enhanced macrophage chemotaxis, stimulated inflammatory pathways, reduced insulin-stimulated glucose uptake in L6 myocytes, and impaired insulin-mediated suppression of hepatic glucose output in primary mouse hepatocytes. This was accompanied by lower insulin-stimulated Akt phosphorylation and higher Irs-1/2 serine phosphorylation, and all of these events were dependent on Gai and Jnk1, two downstream mediators of Ltb4r1 signaling. These observations elucidate a novel role of the LTB4-Ltb4r1 signaling pathway in hepatocyte and myocyte insulin resistance, and they show that in vivo inhibition of Ltb4r1 leads to robust insulin-sensitizing effects.
Insulin resistance is a characteristic feature of patients with type 2 diabetes mellitus [1] [2] [3] [4] . Obesity is the major cause of insulin resistance, and the current obesity epidemic in westernized countries is driving the parallel type 2 diabetes epidemic. Insulin resistance is a complex pathophysiologic defect characterized by impaired insulin signaling in metabolic tissues. Inflammatory mediators such as cytokines, eicosanoids, and other factors participate in causing decreased insulin signaling, and other mechanisms, such as lipotoxicity, can also contribute to insulin resistance 5, 6 . A role for proinflammatory signaling as a cause of insulin resistance was proposed a number of years ago 7, 8 and evidence supporting this concept has gradually increased since then 9 . For example, in obesity, there is a greater accumulation of immune cells in the insulin target tissues adipose tissue 10, 11 , liver 12 and muscle 13 , and this chronic tissue inflammatory state has a key causal role in obesityinduced insulin resistance 14 . In visceral fat from obese subjects, macrophages can account for 40% of the total cell number and secrete a variety of factors that could impair insulin signaling. In addition, other immune cell types, such as lymphocytes, eosinophils, and neutrophils also contribute to the tissue inflammatory state in obesity 9, [15] [16] [17] .
Leukotriene B 4 (LTB4) is a proinflammatory lipid mediator generated from arachidonic acid through the sequential activities of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene A 4 hydrolase 18 . LTB4 exerts well-characterized biological actions, including the promotion of leukocyte chemotaxis and the regulation of proinflammatory cytokines by binding to a G protein-coupled receptor termed Ltb4r1 or Ltb4r2 (refs. 19-21) . Ltb4r1 (also known as Blt1) is the high-affinity receptor specific for LTB4, and it is expressed in a variety of inflammatory and immune cells, including granulocytes, eosinophils, macrophages, differentiated type 1 helper T cells (T H 1 cells), T H 2 and T H 17 cells, effector CD8 T cells, dendritic cells and osteoclasts. Ltb4r2 (Blt2) is a low-affinity receptor and is expressed more ubiquitously [19] [20] [21] .
It has reported that the LTB4-Ltb4r1 axis has an important role in host defense during acute infection. Chronic activation of the LTB4-Ltb4r1 system can also contribute to persistent inflammation characteristic of inflammatory pathologies, including atherosclerosis and arthritis [22] [23] [24] . One recent study showed that Ltb4r1-knockout (KO) mice were protected from inflammation and insulin resistance 25 , thereby indicating a role for LTB4 in metabolic dysfunction. In the current study, we report that an Ltb4r1 selective smallmolecule inhibitor [26] [27] [28] [29] [30] markedly reduces tissue inflammation and insulin resistance, both in diet-induced and genetic-mediated obese mouse models. Moreover, we unexpectedly found that, apart from its potent proinflammatory and chemotactic actions, LTB4 can directly induce decreased insulin signaling in myocytes and hepatocytes. All of these findings suggest that Ltb4r1 could be a valuable drug target for the treatment of inflammation and insulin resistance.
RESULTS

Inhibition of Ltb4r1 improves metabolism
We have found that HFD-induced obese mice exhibit higher concentrations of LTB4 (2-3 fold) in muscle, liver, and adipose tissue, compared to chow-fed lean mice (Fig. 1a) . Based on this observation, we conducted genetic-and pharmacologic-based loss-of-function studies to assess the role of the LTB4-Ltb4r1 system in obesityassociated tissue inflammation and insulin resistance. When placed on a HFD (60% kcal from fat) for 12 weeks, Ltb4r1-KO and wild-type (WT) mice achieved the same degree of obesity (Fig. 1b) , whereas glucose tolerance and hyperinsulinemia were markedly better in the KO mice compared to the WT mice (Fig. 1b,c) . In addition, the glucose-lowering effects of insulin were greater in the KO mice compared to WT mice (Fig. 1c) , indicating an insulin-sensitive phenotype upon genetic deletion of Ltb4r1. In contrast, there were no effects of the Ltb4r1 KO on glucose metabolism in lean chow-fed mice ( Supplementary  Fig. 1 ). These results in the HFD-fed Ltb4r1-KO mice are fully consistent with a previous study 25 .
To further define the role of the LTB4-Ltb4r1 system and to assess its potential for successful translational medicine, we treated WT male HFD-fed mice with the Ltb4r1-specific inhibitor CP105696 (refs. 26-30) . This compound is highly selective for Ltb4r1 versus Ltb4r2 (ref. 26) , and its structure is provided in refs. 29 and 30. We fed WT mice HFD for 14 weeks and, starting at week 12 of the HFD regimen, the mice were given vehicle or the Ltb4r1 inhibitor (50 mg kg −1 ) by oral gavage. Consistent with the phenotype of the KO mice, treatment with the Ltb4r1 inhibitor resulted in markedly greater glucose tolerance (Fig. 1d) as well as in glucose lowering after injected insulin (Fig. 1e) compared to vehicle-treated mice without any change in body weight (Fig. 1f) . Ltb4r1 inhibitor treatment also resulted in lower serum insulin and free fatty acid (FFA) levels (Fig. 1f) . Similarly to male mice, ovariectomized (OVX) female mice gain weight on HFD and become insulin resistant. Therefore, we treated HFD-fed, OVX mice with the Ltb4r1 inhibitor and observed comparable beneficial effects as in the male mice (Supplementary Fig. 2 ). Together, these results indicate that the Ltb4r1 inhibitor confers a systemic insulinsensitive phenotype in diet-induced obesity.
To quantify this effect on improved insulin sensitivity and to identify tissue-specific responses in the muscle, liver and adipose tissue in vivo, we performed hyperinsulinemic-euglycemic clamp studies on a cohort of WT mice placed on a 14-week HFD regimen and treated with either the Ltb4r1 inhibitor or vehicle for the last 2 weeks of the diet, as described above for Figure 1d . The Ltb4r1 inhibitortreated mice were substantially more insulin sensitive compared to the (Fig. 1g-i) . This improvement in insulin sensitivity was manifested by a higher overall glucose infusion rate (GIR) (Fig. 1g) . In addition, the inhibitor-treated mice exhibited an enhanced insulin-stimulated glucose disposal rate (IS-GDR, a measure of skeletal muscle insulin sensitivity) (Fig. 1g) , as well as a greater ability of insulin to suppress both hepatic glucose production (HGP) (Fig. 1h) and circulating FFA levels ( Fig. 1i) (a measure of adipose tissue insulin sensitivity). Thus, Ltb4r1 inhibitor treatment led to greater in vivo insulin sensitivity in all three major insulin target tissues: muscle, liver and fat. Furthermore, treatment of genetically obese (ob/ob) mice with the Ltb4r1 inhibitor for 2 weeks also led to better glucose tolerance compared to vehicle-treated ob/ob mice, but without a change in body weight, and with lower insulin levels (Fig. 1j) .
Effect of Ltb4r1 inhibition on macrophage chemotaxis
It is known that LTB4 is a potent chemokine for macrophages, neutrophils and T cells. We found that LTB4 stimulated chemotaxis of mouse intraperitoneal macrophages (IP-macs) in a dose-dependent manner ( Fig. 2a) , and pretreatment of the IP-macs with the Ltb4r1 inhibitor blocked LTB4-induced chemotaxis (Fig. 2b) . 3T3-L1 differentiated adipocyte-conditioned medium (CM) contains a mixture of different chemokines, including Ccl2, Cxcl1, and LTB4. The Ltb4r1 inhibitor abolished CM-induced chemotaxis of both mouse IP-macs and a human macrophage cell line U-937 without causing cell toxicity (Fig. 2c,d and Supplementary Fig. 3 ), indicating that LTB4 is an important chemokine in adipose tissue CM. To determine if these in vitro chemotaxis results translated to the in vivo condition, we directly measured macrophage migration into adipose tissue using an in vivo macrophage-tracking technique 31 . With this approach, circulating monocytes were obtained from a WT donor mouse and labeled with fluorescent PKH26 dye ex vivo. The labeled monocytes were then injected into recipient HFD-fed WT mice treated with the Ltb4r1 inhibitor or vehicle. We found a substantially lower degree of labeled macrophages in adipose tissue in the Ltb4r1 inhibitor-treated mice compared to vehicle-treated mice (Fig. 2e) . These data were more revealing when we examined the subpopulations of labeled macrophages between the groups. Adipose tissue macrophages (ATMs) expressing Cd11c are M1-like and proinflammatory compared to M2-like Cd11c-negative ATMs, which are noninflammatory 32 . By using FACS analysis, we found that there is an even lower number of recruited macrophages which express Cd11c, while there is a higher number of the Cd11c − macrophages population in the Ltb4r1 inhibitor-treated mice (Fig. 2e) . Indeed, the ratio of M1/M2 ATMs is changed from ninefold to twofold in the vehicle-treated mice compared to the inhibitor-treated mice, indicative of improved adipose tissue homeostasis induced by Ltb4r1 inhibitor treatment (Fig. 2e) .
We also conducted in vivo monocyte tracking experiments with donor monocytes from either WT mice or Ltb4r1-KO mice injected into WT HFD-fed obese mice. We found that the ability of Ltb4r1-KO monocytes to migrate into adipose tissue was substantially impaired compared to WT cells (Fig. 2f) , providing further support for the concept of lower macrophage migration into tissues of Ltb4r1 inhibitor-treated mice. Consistent with the IP-mac chemotaxis and in vivo migration results, we found lower amounts of Cd11c + ATMs in Ltb4r1 inhibitor-treated mice ( Fig. 2g and Supplementary Fig. 4) . Additionally, in ob/ob mice Ltb4r1 inhibition led to lower amounts of Cd11c + ATMs and adipose tissue neutrophils (ATNs) but to higher Cd11c − ATM content (Fig. 2h) .
LTB4 and Ltb4r1 induce inflammation
Consistent with the lower ATM accumulation in HFD-fed Ltb4r1 inhibitor-treated mice compared to HFD-fed vehicle-treated mice, we also found lower expression of a number of proinflammatory genes typically associated with the inflammatory-induced insulin resistant state in epididymal white adipose tissue (epi-WAT) in the former group of mice versus the latter (Fig. 3a) . At the same time, higher expression of anti-inflammatory genes, including Il10, Mgl1, Clec7a, Mrc1, and Il4, was observed in epi-WAT from the inhibitor-treated mice compared to the vehicle-treated ones (Fig. 3b) . In addition to tissue inflammation, circulating cytokine levels are elevated in obesity, and inhibitor treatment of HFD-fed mice resulted in lower levels of various proinflammatory cytokines, as exemplified by Il-6, Ccl5, Tnf, and Il-12p40, compared to HFD-fed, vehicle-treated mice ( Fig. 3c-f) . Epi-WAT mass and adipocyte size were not changed by Ltb4r1 inhibitor treatment (Supplementary Fig. 5a,b) .
Lower ATM content is one explanation for the lower expression of proinflammatory markers in adipose tissue and blood (Figs. 2 and 3) in Ltb4r1 inhibitor-treated mice. In addition, we considered the possibility that LTB4 could also directly activate intrinsic ATM proinflammatory pathways. To this end, we evaluated LTB4-mediated inflammatory stimulation in isolated IP-macs from WT and Ltb4r1-KO mice. We found that LTB4 stimulated phosphorylation of Ikk-β and Jnk and promoted IκB degradation (Fig. 4a) ; these three proteins are involved in the inflammatory pathway of these cells.
To further demonstrate that LTB4 and Ltb4r1 promote macrophage inflammation, we measured the mRNA expression of different proinflammatory and anti-inflammatory genes by quantitative PCR (qPCR). LTB4 treatment of IP-macs resulted in higher inflammatory cytokine gene expression, as was observed in Tnf, Il6, Cxcl1, and Ccl2 (Fig. 4b) , but it did not affect the expression of anti-inflammatory genes (Fig. 4c) compared to vehicle-treated controls. The Ltb4r1 inhibitor blocked LPSinduced Jnk activation in IP-macs from WT mice but not from Ltb4r1-KO mice (Fig. 4d) , suggesting a broader role for the LTB4-Ltb4r1 system in inflammatory responses. Further, LPS-stimulated inflammatory gene expression was lower in Ltb4r1-KO cells compared to WT cells, and the Ltb4r1 inhibitor lowered the LPS responses in WT IP-macs to those observed in Ltb4r1-KO cells, whereas the compound had no effect in Ltb4r1-KO IP-macs ( Fig. 4e-j) .
LTB4 directly induces cellular insulin resistance
Obesity-associated chronic tissue inflammation is a key mechanism for reduced insulin sensitivity, and the anti-inflammatory effects of the Ltb4r1 inhibitor or Ltb4r1 KO could explain the insulinsensitizing effects due to Ltb4r1 loss of function. LTB4 levels are elevated in all three major insulin target tissues, muscle, liver, and adipose from HFD-fed obese mice (Fig. 1) . Furthermore, we found that Ltb4r1 is well expressed in L6 myocytes and hepatocytes, but not in 3T3-L1 adipocytes (Fig. 5a) . Therefore, we explored the effect of LTB4 on L6 myocytes and found that it directly inhibits insulin-stimulated glucose transport by ~50% (Fig. 5b) . This LTB4 effect is accompanied by reduced insulin-stimulated Akt phosphorylation (Fig. 5b) . Further, LTB4 treatment inhibited glucose transporter type 4 (Glut4) translocation in these cells ( Supplementary  Fig. 5c ), consistent with direct interference with insulin signaling in myocytes. As Ltb4r1 signaling can couple with Gαi, we pretreated cells with the Gαi inhibitor pertussis toxin (PT). We found that this pretreatment blocked the effect of LTB4 to inhibit glucose transport (Fig. 5b) , indicating that Gαi mediates these LTB4-mediated actions. In addition, PT treatment blocked the effects of LTB4 on the inhibition of insulin-stimulated Akt phosphorylation (Supplementary Fig. 6 ).
Insulin receptor substrate 1 (Irs1) serine phosphorylation can impair its downstream signaling, and it is well known that specific serine kinases can target Irs1. In our studies, we found that inhibition of Ikk-β or Erk by siRNA knockdown or small-molecule inhibitors did not block the effects of LTB4 on Irs1 serine phosphorylation or subsequent steps in downstream insulin signaling (data not shown). In contrast, our data indicate that Jnk activation is the likely intervening mechanism (Fig. 5c-i) . Thus, we explored the effect of LTB4 on Jnk phosphorylation (pJnk), as a readout of Jnk stimulation, and found that LTB4 at two different concentrations promotes higher pJnk levels compared to untreated cells or cells treated with insulin alone (Fig. 5c) . Depletion of Jnk from L6 myocytes with siRNA is sufficient to completely block the effect of LTB4 treatment on inhibition of insulin-stimulated glucose transport (Fig. 5d) . Consistent with this, Jnk depletion also blocks the effect of LTB4 on inhibition of insulin-stimulated Akt phosphorylation, and it completely prevents augmentation of Irs1 serine phosphorylation by LTB4 treatment (Fig. 5d) . Finally, we used a small-molecule inhibitor of Jnk activity and found that pharmacologic Jnk inhibition had the same effects as siRNA depletion on LTB4-induced cellular insulin resistance in L6 myocytes (Supplementary Fig. 7) . Taken together, these data are consistent with the view that LTB4 promotes cellular insulin resistance through a Gαi-coupled mechanism, which promotes Jnk activation, thereby leading to subsequent Irs1 serine phosphorylation with decreased downstream signaling through Akt to glucose transport in L6 cells.
In WT primary hepatocytes in vitro, we found that glucagon stimulates hepatic glucose output (HGO) and that this effect was completely inhibited by insulin (Fig. 5e) . LTB4 treatment of WT hepatocytes directly stimulated HGO but did not affect Ltb4r1-KO hepatocytes (Fig. 5e) . This effect of LTB4 on stimulation of HGO in WT cells was not inhibited by insulin, consistent with an LTB4-induced cellular insulin resistant state. Further, LTB4 treatment blocked the effect of npg insulin on inhibition of glucagon-stimulated HGO in WT hepatocytes, but was without inhibitory effect in KO cells (Fig. 5e) . Thus, LTB4 stimulation can promote HGO by itself and can also attenuate the normal inhibitor effect of insulin on this aspect of hepatic metabolism. Showing the specificity of this effect, LTB4-stimulated HGO can be completely blocked by Ltb4r1 inhibitor treatment ( Supplementary  Fig. 8a) . The overall effect of glucagon on increasing HGO was less robust in Ltb4r1-KO cells compared to WT cells (Fig. 5e) ; the reason for this is unknown.
We also found that although insulin-stimulated Akt phosphorylation in WT primary hepatocytes was quite potent, this effect was completely inhibited by concomitant treatment with LTB4 (Fig. 5f) . In contrast, LTB4 had no effect on the ability of insulin to promote Akt phosphorylation in Ltb4r1-KO hepatocytes (Fig. 5f) . Similar to the results in L6 myocytes, LTB4 treatment led to hepatocyte Irs2 serine 307 phosphorylation (Fig. 5g) . These effects of LTB4 that directly cause hepatocyte insulin resistance are mediated through Gαi signaling, as demonstrated by the fact that PT treatment prevented the effects of LTB4 on blocking insulin-mediated inhibition of glucagon-stimulated HGO (Fig. 5h) , and it also blocked the ability of LTB4 to inhibit insulin-stimulated Akt phosphorylation (Supplementary Fig. 8b) . As with the L6 cells, siRNAmediated depletion of Jnk blocked the effects of LTB4 on hepatocyte insulin resistance in terms of HGO suppression (Fig. 5i) .
In contrast to the effects of the LTB4-Ltb4r1 system on insulin action in myocytes and hepatocytes, LTB4 did not inhibit insulinstimulated glucose transport in 3T3-L1 adipocytes ( Supplementary  Fig. 8c ). This is fully consistent with the results showing that Ltb4r1 is not expressed in these cells (Fig. 5a) . group (a,b,d ,e,h-j). Western blot data are representative of more than three independent experiments. ## P < 0.01 for KO versus WT in e, *P < 0.05, **P < 0.01 in b,d,e,h-j.
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To dissect the contribution of these different effects of LTB4 on insulin resistance in vivo, we depleted macrophages in control and Ltb4r1 inhibitor-treated mice by clodronate injection. Consistent with previous findings, the clodronate injection is associated with better glucose tolerance in HFD-fed mice compared to vehicle (PBS)-treated HFD mice, and this is accompanied by lower circulating insulin levels (Fig. 5j) , showing that depletion of macrophages alone is sufficient to greatly improve insulin resistance. However, mice treated with clodronate and the Ltb4r1 inhibitor were ~40% more glucose tolerant than the vehicle/clodronate-treated group with a further ~60% lowering of plasma insulin levels (Fig. 5j) , and these values are even lower than the glucose and insulin levels in chow-fed mice ( Supplementary  Fig. 1 ). These results indicate that the in vivo insulin-sensitizing effects of the Ltb4r1 inhibitor are mediated through a combination of an anti-inflammatory effect in immune cells and a direct insulinsensitizing effect on insulin target cells.
Hepatic lipid profiles
It is known that HFD-induced obesity leads to marked hepatosteatosis 33, 34 . After 2 weeks of Ltb4r1 inhibitor treatment, hepatic fat accumulation was largely absent in both HFD-fed and ob/ob obese mice (Fig. 6a) , and this was accompanied by reduced expression of the lipogenic genes Nr1h3, Srebf1 and Ldlr (Fig. 6b) .
In primary hepatocytes, we found that LTB4 treatment directly augmented de novo synthesis of hepatic DAGs and ceramides (Fig. 6c,d) . Because ceramide and DAGs have been reported to inhibit insulin action [35] [36] [37] [38] [39] , LTB4 might induce higher amounts of these lipids in vivo, thereby providing a possible further mechanism for LTB4-mediated hepatic insulin resistance.
DISCUSSION
Here we show that inhibition of Ltb4r1 results in an anti-inflammatory phenotype with protection from systemic insulin resistance in the setting of both HFD-induced and genetic-mediated obesity. This robust phenotype in the Ltb4r1 inhibitor-treated mice was manifested by less macrophage accumulation in adipose tissue, lower expression of inflammatory pathway genes, lower blood cytokine levels, and less hepatic steatosis compared to vehicle-treated mice. In addition, we observed better glucose tolerance, as well as systemic insulin sensitivity as measured by the hyperinsulinemic-euglycemic clamp method, in Ltb4r1 inhibitor-treated animals versus controls. In contrast, treatment with LTB4 both stimulated inflammatory pathways in macrophages and directly caused cellular insulin resistance in hepatocytes and myocytes.
This improvement in inflammatory status and insulin sensitivity with Ltb4r1 inhibitor treatment reinforces the connection between chronic tissue inflammation and insulin resistance. Given that macrophages, other immune cells and insulin target cells can all produce LTB4, LTB4's effect on promoting inflammation, along with its direct effects on cellular insulin resistance in hepatocytes and myocytes, adds a new layer of understanding to the inflammationinsulin resistance syndrome.
There is a substantial body of literature showing that LTB4 is a potent chemotatic factor operating through Ltb4r1 and Ltb4r2 (refs. 40,41) . Ltb4r1 is more specifically distributed on macrophages, neutrophils 42 and lymphocytes 43 , and both the KO mice and mice treated with Ltb4r1 inhibitor are representative of specific lossof-function studies directed only at Ltb4r1. These studies suggest that obesity-associated production of LTB4 by primary tissue cells such as adipocytes, hepatocytes, myocytes, endothelial cells, or other resident tissue cell types could be an early trigger for the chronic tissue inflammatory state in obesity. LTB4 acts as a powerful chemokine, working through Ltb4r1 on immune cell types, to cause chemotaxis and migration into tissues. Strong support for this notion comes from the in vitro chemotaxis and in vivo monocyte tracking experiments in HFD and ob/ob mice. Thus, Ltb4r1 inhibition impairs chemotaxis and tracking of monocytes and other immune cells into adipose tissue, inhibiting the ultimate inflammation-insulin resistance syndrome. This is consistent with recent studies in Ltb4r1-KO mice, which show an anti-inflammatory phenotype along with improved glucose tolerance and insulin sensitivity 25 .
It is important to note that recruited immune cells can also produce LTB4, setting up a positive-reinforcing vicious cycle. Thus, tissue cells such as adipocytes produce LTB4, which recruits and activates ATMs; these immune cells then produce more LTB4, further propagating the chronic tissue inflammatory response. This could be a new mechanism for inflammation-induced insulin resistance, because LTB4 is downstream of all the major proinflammatory pathways and is elevated in the three key insulin target tissues. This is consistent with other studies showing higher LTB4 levels in adipose tissue in obesity 44 . 5-LO-activating protein (FLAP) plays a role in the generation of LTB4 from arachidonic acid (AA) and the elevated levels of AA and FLAP have been reported in obesity [44] [45] [46] , thus providing a potential mechanism for the higher LTB4 concentrations in tissues from HFD mice (Fig. 1) .
One of the novel findings in this study is that LTB4 can directly cause insulin resistance in muscle and liver cells. This component of insulin resistance is independent of effects of the LTB4-Ltb4r1 npg pathway to promote tissue inflammation. Although production of LTB4 is part of an inflammatory response, in a certain sense this can be looked at as a more direct mechanism of insulin resistance. As demonstrated, this mechanism operates in both myocytes and hepatocytes, but not in adipocytes, as the latter do not express Ltb4r1.
Since the hyperinsulinemic-euglycemic clamp studies demonstrate systemic insulin resistance in all three major insulin target tissues, we conclude that the adipose tissue insulin sensitivity conferred by Ltb4r1 inhibitor treatment is mainly due to attenuation of the adipose tissue inflammatory response. With respect to mechanisms of the direct effects of LTB4 to induce insulin resistance, our studies indicate that LTB4 works specifically through Ltb4r1 and Gαi in hepatocytes and myocytes to interfere with proximal steps of insulin signaling. Furthermore, we found that LTB4 stimulated Jnk kinase activity, mediating the inhibitory Irs1 and Irs2 serine phosphorylation events. Both genetic and pharmacologic Jnk loss of function inhibits all the effects of LTB4 to induce cellular insulin resistance in isolated hepatocytes and L6 myocytes. Taken together, these results provide a reasonable Gαi-and Jnk-dependent molecular mechanism for LTB4-induced cellular insulin resistance.
Our data indicate that these direct effects of LTB4 causing reduced myocyte and hepatocyte insulin sensitivity are operative in vivo. Thus, macrophage depletion in clodronate-treated mice caused a marked improvement in glucose tolerance and hyperinsulinemia, whereas clodronate plus Ltb4r1 inhibitor treatment led to a 40-60% further reduction in glucose or insulin levels, respectively. This is consistent with the view that blockade of Ltb4r1 in vivo can improve insulin signaling by both attenuating obesity-induced inflammation and interfering with the direct effects of LTB4 that cause cellular insulin resistance.
Although there are probably multiple molecular mechanisms contributing to defects in insulin action 47 , it has been known for several years that chronic tissue inflammation is a key cause of insulin resistance 48 . However, therapeutic efforts to ameliorate this inflammation-induced insulin resistance have had limited success 49 . Whereas some studies have shown glucose-lowering effects of specific TNF-α or IL-1β inhibitors 50, 51 , these agents have had little to no effect on improving insulin sensitivity in clinical studies [49] [50] [51] [52] [53] , Even the more general anti-inflammatory agent salsalate has had only modest effects 49, [54] [55] [56] . IL-1β inhibition does lead to glucose-lowering effects 57, 58 , but these have been ascribed to enhanced beta cell functions, not improved insulin sensitivity 50, 57, 58 . On the basis of the current studies, one can raise the possibility that these therapeutic modalities are not fully directed at the key mechanisms for insulin resistance and that attempts to inhibit the LTB4-Ltb4r1 system might be more efficacious.
In summary, these results show that LTB4 is overexpressed in insulin target tissues in obesity and that the LTB4-Ltb4r1 system is a major driver for the inflammation-insulin resistance syndrome. Thus, LTB4 is a potent chemokine that promotes migration of monocytes into adipose tissue and directly stimulates macrophage Ltb4r1 to activate intracellular proinflammatory pathways. Our studies also reveal a novel additional mechanism for LTB4-induced insulin resistance. Thus, in vitro, LTB4 directly caused reduced insulin sensitivity in hepatocytes and myocytes. This cytokine-independent mechanism of insulin resistance provides a new mechanism connecting inflammation and impaired insulin sensitivity. As such, it is possible that inhibition of LTB4 action could be a useful future therapeutic goal in the treatment of insulin-resistance diseases.
METHODS
Methods and any associated references are available in the online version of the paper. 
